FDA Nears Decision on Atacicept for Rare Kidney Disease Treatment

The U.S. Food and Drug Administration is anticipated to make a decision today regarding the accelerated approval of atacicept. This drug is intended to treat immunoglobulin A nephropathy (IgAN), a rare autoimmune kidney disorder. Interim trial data has shown promising results in reducing proteinuria for patients with this condition.